111 related articles for article (PubMed ID: 19695230)
21. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.
Devine T; Dai MS
Curr Pharm Des; 2013; 19(18):3248-62. PubMed ID: 23151129
[TBL] [Abstract][Full Text] [Related]
22. The role of the ubiquitin proteasome system in lymphoma.
Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A
Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070
[TBL] [Abstract][Full Text] [Related]
23. Combination of quercetin and tannic acid in inhibiting 26S proteasome affects S5a and 20S expression, and accumulation of ubiquitin resulted in apoptosis in cancer chemoprevention.
Chang TL; Wang CH
Biol Chem; 2013 Apr; 394(4):561-75. PubMed ID: 23241588
[TBL] [Abstract][Full Text] [Related]
24. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis.
Li Y; Zhou Z; Chen C
Cell Death Differ; 2008 Dec; 15(12):1941-51. PubMed ID: 18806757
[TBL] [Abstract][Full Text] [Related]
25. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
[TBL] [Abstract][Full Text] [Related]
26. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.
Dogra N; Mukhopadhyay T
J Biol Chem; 2012 Aug; 287(36):30625-40. PubMed ID: 22745125
[TBL] [Abstract][Full Text] [Related]
27. Transient arrest in proteasomal degradation during inhibition of translation in the unfolded protein response.
Shenkman M; Tolchinsky S; Kondratyev M; Lederkremer GZ
Biochem J; 2007 Jun; 404(3):509-16. PubMed ID: 17338678
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?
Basbous J; Jariel-Encontre I; Gomard T; Bossis G; Piechaczyk M
Biochimie; 2008 Feb; 90(2):296-305. PubMed ID: 17825471
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis of ubiquitinated proteins in normal hepatocyte cell line Chang liver cells.
Tan F; Lu L; Cai Y; Wang J; Xie Y; Wang L; Gong Y; Xu BE; Wu J; Luo Y; Qiang B; Yuan J; Sun X; Peng X
Proteomics; 2008 Jul; 8(14):2885-96. PubMed ID: 18655026
[TBL] [Abstract][Full Text] [Related]
30. Regulation of ubiquitin and 26S proteasome mediated by phenolic compounds during oxidative stress.
Chang TL; Lin SW; Wu SL; Hong CM
J Nutr Biochem; 2013 Nov; 24(11):1970-81. PubMed ID: 24075904
[TBL] [Abstract][Full Text] [Related]
31. c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1.
Xu L; Zhu J; Hu X; Zhu H; Kim HT; LaBaer J; Goldberg A; Yuan J
Mol Cell; 2007 Dec; 28(5):914-22. PubMed ID: 18082613
[TBL] [Abstract][Full Text] [Related]
32. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.
Anchoori RK; Khan SR; Sueblinvong T; Felthauser A; Iizuka Y; Gavioli R; Destro F; Isaksson Vogel R; Peng S; Roden RB; Bazzaro M
PLoS One; 2011; 6(8):e23888. PubMed ID: 21909374
[TBL] [Abstract][Full Text] [Related]
33. c-Fos degradation by the ubiquitin-proteasome proteolytic pathway in osteoclast progenitors.
Ito Y; Inoue D; Kido S; Matsumoto T
Bone; 2005 Dec; 37(6):842-9. PubMed ID: 16172035
[TBL] [Abstract][Full Text] [Related]
34. An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro.
Zhu H; Wang T; Xin Z; Zhan Y; Gu G; Li X; Wang X; Yang S; Liu C
Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(10):1034-1040. PubMed ID: 31518420
[TBL] [Abstract][Full Text] [Related]
35. Gankyrin: a new oncoprotein and regulator of pRb and p53.
Dawson S; Higashitsuji H; Wilkinson AJ; Fujita J; Mayer RJ
Trends Cell Biol; 2006 May; 16(5):229-33. PubMed ID: 16581249
[TBL] [Abstract][Full Text] [Related]
36. p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner.
Karni-Schmidt O; Zupnick A; Castillo M; Ahmed A; Matos T; Bouvet P; Cordon-Cardo C; Prives C
J Cell Sci; 2008 Dec; 121(Pt 24):4098-105. PubMed ID: 19033390
[TBL] [Abstract][Full Text] [Related]
37. Complex mechanisms for c-fos and c-jun degradation.
Jariel-Encontre I; Salvat C; Steff AM; Pariat M; Acquaviva C; Furstoss O; Piechaczyk M
Mol Biol Rep; 1997 Mar; 24(1-2):51-6. PubMed ID: 9228281
[TBL] [Abstract][Full Text] [Related]
38. Targeting the ubiquitin-proteasome system for cancer therapy.
Yang Y; Kitagaki J; Wang H; Hou DX; Perantoni AO
Cancer Sci; 2009 Jan; 100(1):24-8. PubMed ID: 19037995
[TBL] [Abstract][Full Text] [Related]
39. Immediate early gene-X1 interferes with 26 S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2.
Arlt A; Minkenberg J; Kruse ML; Grohmann F; Fölsch UR; Schäfer H
Biochem J; 2007 Mar; 402(2):367-75. PubMed ID: 17107344
[TBL] [Abstract][Full Text] [Related]
40. Knocking out ubiquitin proteasome system function in vivo and in vitro with genetically encodable tandem ubiquitin.
Saeki Y; Isono E; Shimada M; Kawahara H; Yokosawa H; Toh-E A
Methods Enzymol; 2005; 399():64-74. PubMed ID: 16338349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
